Cargando…

Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers

Hepatocellular carcinoma (HCC) is the fifth most common cancer and advanced hepatic fibrosis is a major risk factor for HCC. Hepatic fibrosis including liver cirrhosis and HCC are mainly induced by persistent hepatitis B or C virus infection, with approximately 500 million people infected with hepat...

Descripción completa

Detalles Bibliográficos
Autores principales: Uto, Hirofumi, Kanmura, Shuji, Takami, Yoichiro, Tsubouchi, Hirohito
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023778/
https://www.ncbi.nlm.nih.gov/pubmed/21192835
http://dx.doi.org/10.1186/1477-5956-8-70
_version_ 1782196703698354176
author Uto, Hirofumi
Kanmura, Shuji
Takami, Yoichiro
Tsubouchi, Hirohito
author_facet Uto, Hirofumi
Kanmura, Shuji
Takami, Yoichiro
Tsubouchi, Hirohito
author_sort Uto, Hirofumi
collection PubMed
description Hepatocellular carcinoma (HCC) is the fifth most common cancer and advanced hepatic fibrosis is a major risk factor for HCC. Hepatic fibrosis including liver cirrhosis and HCC are mainly induced by persistent hepatitis B or C virus infection, with approximately 500 million people infected with hepatitis B or C virus worldwide. Furthermore, the number of patients with non-alcoholic fatty liver disease (NAFLD) has recently increased and NAFLD can progress to cirrhosis and HCC. These chronic liver diseases are major causes of morbidity and mortality, and the identification of non-invasive biomarkers is important for early diagnosis. Recent advancements in quantitative and large-scale proteomic methods could be used to optimize the clinical application of biomarkers. Early diagnosis of HCC and assessment of the stage of hepatic fibrosis or NAFLD can also contribute to more effective therapeutic interventions and an improve prognosis. Furthermore, advancements of proteomic techniques contribute not only to the discovery of clinically useful biomarkers, but also in clarifying the molecular mechanisms of disease pathogenesis by using body fluids, such as serum, and tissue samples and cultured cells. In this review, we report recent advances in quantitative proteomics and several findings focused on liver diseases, including HCC, NAFLD, hepatic fibrosis and hepatitis B or C virus infections.
format Text
id pubmed-3023778
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30237782011-01-20 Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers Uto, Hirofumi Kanmura, Shuji Takami, Yoichiro Tsubouchi, Hirohito Proteome Sci Review Hepatocellular carcinoma (HCC) is the fifth most common cancer and advanced hepatic fibrosis is a major risk factor for HCC. Hepatic fibrosis including liver cirrhosis and HCC are mainly induced by persistent hepatitis B or C virus infection, with approximately 500 million people infected with hepatitis B or C virus worldwide. Furthermore, the number of patients with non-alcoholic fatty liver disease (NAFLD) has recently increased and NAFLD can progress to cirrhosis and HCC. These chronic liver diseases are major causes of morbidity and mortality, and the identification of non-invasive biomarkers is important for early diagnosis. Recent advancements in quantitative and large-scale proteomic methods could be used to optimize the clinical application of biomarkers. Early diagnosis of HCC and assessment of the stage of hepatic fibrosis or NAFLD can also contribute to more effective therapeutic interventions and an improve prognosis. Furthermore, advancements of proteomic techniques contribute not only to the discovery of clinically useful biomarkers, but also in clarifying the molecular mechanisms of disease pathogenesis by using body fluids, such as serum, and tissue samples and cultured cells. In this review, we report recent advances in quantitative proteomics and several findings focused on liver diseases, including HCC, NAFLD, hepatic fibrosis and hepatitis B or C virus infections. BioMed Central 2010-12-31 /pmc/articles/PMC3023778/ /pubmed/21192835 http://dx.doi.org/10.1186/1477-5956-8-70 Text en Copyright ©2010 Uto et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Uto, Hirofumi
Kanmura, Shuji
Takami, Yoichiro
Tsubouchi, Hirohito
Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers
title Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers
title_full Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers
title_fullStr Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers
title_full_unstemmed Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers
title_short Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers
title_sort clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023778/
https://www.ncbi.nlm.nih.gov/pubmed/21192835
http://dx.doi.org/10.1186/1477-5956-8-70
work_keys_str_mv AT utohirofumi clinicalproteomicsforliverdiseaseapromisingapproachfordiscoveryofnovelbiomarkers
AT kanmurashuji clinicalproteomicsforliverdiseaseapromisingapproachfordiscoveryofnovelbiomarkers
AT takamiyoichiro clinicalproteomicsforliverdiseaseapromisingapproachfordiscoveryofnovelbiomarkers
AT tsubouchihirohito clinicalproteomicsforliverdiseaseapromisingapproachfordiscoveryofnovelbiomarkers